Last 12 months
Inside the activity.
5 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 2 | 0 |
| Sep 2026 | 1 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2022 Filed Apr 5, 2022 20:40 UTC |
Parikh Shamik JChief Medical Officer
|
GrantStock Options (right to buy) · Derivative | 144,927 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001818382-22-000023 · wf-form4_164919121747205.xml · derivative · entry 1 Parikh Shamik J · CIK 0001916853 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,927 Underlying: Common Stock · 144,927 shares Expires 2032-04-04 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on April 4, 2023, after which 1/48 of the option will become exercisable on the 4th of each month through August 4, 2026. Read SEC document |
| December 16, 2021 Filed Dec 16, 2021 19:46 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
SaleCommon Stock | 75,000 | $9.00 | $675,000.00 |
DisclosureSEC source: 0001104659-21-150678 · tm2135715-1_4seq1.xml · nonDerivative · entry 4 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 510,161 F5 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.79 to $9.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2021 Filed Dec 16, 2021 19:47 UTC |
Dougan Brady WDirector · 10% owner
|
SaleCommon Stock | 75,000 | $9.00 | $675,000.00 |
DisclosureSEC source: 0001104659-21-150679 · tm2135715-2_4seq1.xml · nonDerivative · entry 4 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,161 F5 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.79 to $9.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 19:46 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
SaleCommon Stock | 125,000 | $8.89 | $1,110,625.00 |
DisclosureSEC source: 0001104659-21-150678 · tm2135715-1_4seq1.xml · nonDerivative · entry 3 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 585,161 F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.68 to $9.43. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 19:47 UTC |
Dougan Brady WDirector · 10% owner
|
SaleCommon Stock | 125,000 | $8.89 | $1,110,625.00 |
DisclosureSEC source: 0001104659-21-150679 · tm2135715-2_4seq1.xml · nonDerivative · entry 3 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,161 F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.68 to $9.43. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 19:46 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
SaleCommon Stock | 76,306 | $9.33 | $711,553.45 |
DisclosureSEC source: 0001104659-21-150678 · tm2135715-1_4seq1.xml · nonDerivative · entry 2 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 710,161 F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.825 to $9.49. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 19:46 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
SaleCommon Stock | 23,694 | $9.80 | $232,153.81 |
DisclosureSEC source: 0001104659-21-150678 · tm2135715-1_4seq1.xml · nonDerivative · entry 1 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 786,467 F1 · shares: A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Ayabudge LLC of 1,522,500 shares of the Issuer's common stock on August 26, 2021, at a price per share of $10.00. The Reporting Person's spouse has paid the Issuer $71.21, representing the full amount of profit realized in connection with this sale. F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.50 to $10.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 19:47 UTC |
Dougan Brady WDirector · 10% owner
|
SaleCommon Stock | 76,306 | $9.33 | $711,553.45 |
DisclosureSEC source: 0001104659-21-150679 · tm2135715-2_4seq1.xml · nonDerivative · entry 2 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,161 F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.825 to $9.49. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 19:47 UTC |
Dougan Brady WDirector · 10% owner
|
SaleCommon Stock | 23,694 | $9.80 | $232,153.81 |
DisclosureSEC source: 0001104659-21-150679 · tm2135715-2_4seq1.xml · nonDerivative · entry 1 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,467 F1 · shares: A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Ayabudge LLC of 1,522,500 shares of the Issuer's common stock on August 26, 2021, at a price per share of $10.00. The Reporting Person has paid the Issuer $71.21, representing the full amount of profit realized in connection with this sale. F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.50 to $10.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 11:02 UTC |
Constantino Michael T.Director
|
PurchaseCommon Stock | 2,300 | $10.79 | $24,819.76 |
DisclosureSEC source: 0001104659-21-143251 · tm2133808-1_4seq1.xml · nonDerivative · entry 2 Constantino Michael T. · CIK 0001817285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 11:02 UTC |
Constantino Michael T.Director
|
PurchaseCommon Stock | 200 | $10.83 | $2,166.00 |
DisclosureSEC source: 0001104659-21-143251 · tm2133808-1_4seq1.xml · nonDerivative · entry 1 Constantino Michael T. · CIK 0001817285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 15:51 UTC |
Scheessele William JohnChief Commercial Officer
|
GrantStock Options (right to buy) · Derivative | 157,558 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126728 · tm2130120-7_4seq1.xml · derivative · entry 1 Scheessele William John · CIK 0001879378 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,558 Underlying: Common Stock · 157,558 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on August 9, 2022, after which 1/36 of the option will become exercisable on the 9th of each month through August 9, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 15:42 UTC |
Brown Emery N.Director
|
GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126719 · tm2130120-2_4seq1.xml · derivative · entry 1 Brown Emery N. · CIK 0001878691 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 15:39 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126714 · tm2130120-5_4seq1.xml · derivative · entry 1 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 15:40 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126716 · tm2130120-4_4seq1.xml · derivative · entry 1 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 15:31 UTC |
Wallace Max N.Director
|
GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126701 · tm2130120-10_4seq1.xml · derivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 19:43 UTC |
Binder Gordon MDirector
|
GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126721 · tm2130120-1_4seq1.xml · derivative · entry 1 Binder Gordon M · CIK 0001291957 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 19:41 UTC |
Constantino Michael T.Director
|
GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126717 · tm2130120-3_4seq1.xml · derivative · entry 1 Constantino Michael T. · CIK 0001817285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 19:37 UTC |
Pope ToddDirector
|
GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126713 · tm2130120-6_4seq1.xml · derivative · entry 1 Pope Todd · CIK 0001584367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 19:35 UTC |
Sebelius KathleenDirector
|
GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126708 · tm2130120-8_4seq1.xml · derivative · entry 1 Sebelius Kathleen · CIK 0001654316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 19:34 UTC |
Shukla RajivDirector
|
GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126706 · tm2130120-9_4seq1.xml · derivative · entry 1 Shukla Rajiv · CIK 0001709033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 19:29 UTC |
Windham-Bannister Susan RichardsDirector
|
GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126700 · tm2130120-11_4seq1.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Lawson Jeffrey HaroldDirector · Chief Surgical Officer
|
GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 6 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Lawson Jeffrey HaroldDirector · Chief Surgical Officer
|
GrantStock Options (right to buy) · Derivative | 1,194,815 | Not disclosed Strike: $8.48 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 5 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,194,815 Underlying: Common Stock · 1,194,815 shares Expires 2028-06-28 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Lawson Jeffrey HaroldDirector · Chief Surgical Officer
|
GrantStock Options (right to buy) · Derivative | 118,168 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 4 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,168 Underlying: Common Stock · 118,168 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Lawson Jeffrey HaroldDirector · Chief Surgical Officer
|
GrantStock Options (right to buy) · Derivative | 65,649 | Not disclosed Strike: $3.44 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 3 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,649 Underlying: Common Stock · 65,649 shares Expires 2026-12-15 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Lawson Jeffrey HaroldDirector · Chief Surgical Officer
|
GrantStock Options (right to buy) · Derivative | 90,595 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · derivative · entry 2 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,595 Underlying: Common Stock · 90,595 shares Expires 2025-12-11 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC |
Lawson Jeffrey HaroldDirector · Chief Surgical Officer
|
GrantCommon Stock | 7,877 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110526 · tm2125954-17_4seq1.xml · nonDerivative · entry 1 Lawson Jeffrey Harold · CIK 0001879530 · Director · Chief Surgical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,877 F1 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 17,068 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · derivative · entry 13 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 13,129 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · derivative · entry 12 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 13,129 Underlying: Common Stock · 13,129 shares Expires 2025-09-01 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · derivative · entry 11 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F5 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 1,312,984 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · derivative · entry 10 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,312,984 Underlying: Common Stock · 1,312,984 shares Expires 2031-01-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4 · derivative.exercise_date: One-third of the option will vest on each of the three anniversaries after November 9, 2020. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 131,298 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · derivative · entry 9 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,298 Underlying: Common Stock · 131,298 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 262,596 | Not disclosed Strike: $3.44 | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · derivative · entry 8 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,596 Underlying: Common Stock · 262,596 shares Expires 2026-09-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 157,558 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · derivative · entry 7 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,558 Underlying: Common Stock · 157,558 shares Expires 2026-03-09 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 13,129 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · derivative · entry 6 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,129 Underlying: Common Stock · 13,129 shares Expires 2025-09-01 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantStock Options (right to buy) · Derivative | 262,596 | Not disclosed Strike: $1.19 | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · derivative · entry 5 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,596 Underlying: Common Stock · 262,596 shares Expires 2023-11-22 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
PurchaseCommon Stock | 1,522,500 | $10.00 | $15,225,000.00 |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · nonDerivative · entry 3 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ayabudge LLC Disclosed balance after: 20,452,504 Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantCommon Stock | 18,930,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · nonDerivative · entry 2 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ayabudge LLC Disclosed balance after: 18,930,004 F1 · price: On August 26, 2021 , Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:15 UTC |
Niklason Laura EDirector · President, CEO and Director · 10% owner
|
GrantCommon Stock | 1,148,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110547 · tm2125954-26_4seq1.xml · nonDerivative · entry 1 Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,240 F1 · price: On August 26, 2021 , Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:09 UTC |
Sander Dale A.CFO and Chief Corp. Deve. Off.
|
GrantStock Options (right to buy) · Derivative | 210,077 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110523 · tm2125954-15_4seq1.xml · derivative · entry 5 Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,077 Underlying: Common Stock · 210,077 shares Expires 2031-05-16 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F5 · derivative.exercise_date: Options vest annually in three equal installments on 05/14/2022, 05/14/2023, and 05/14/2024. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:09 UTC |
Sander Dale A.CFO and Chief Corp. Deve. Off.
|
GrantStock Options (right to buy) · Derivative | 183,817 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110523 · tm2125954-15_4seq1.xml · derivative · entry 4 Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,817 Underlying: Common Stock · 183,817 shares Expires 2031-01-14 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4 · derivative.exercise_date: Options vest annually in three equal installments on 11/09/2021, 11/09/2022, and 11/09/2023. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:09 UTC |
Sander Dale A.CFO and Chief Corp. Deve. Off.
|
GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110523 · tm2125954-15_4seq1.xml · derivative · entry 3 Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F3 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:09 UTC |
Sander Dale A.CFO and Chief Corp. Deve. Off.
|
GrantStock Options (right to buy) · Derivative | 17,068 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110523 · tm2125954-15_4seq1.xml · derivative · entry 2 Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2028-04-12 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F1 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:09 UTC |
Sander Dale A.CFO and Chief Corp. Deve. Off.
|
GrantStock Options (right to buy) · Derivative | 39,389 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110523 · tm2125954-15_4seq1.xml · derivative · entry 1 Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,389 Underlying: Common Stock · 39,389 shares Expires 2025-09-01 F2 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F1 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 13 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F5 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 1,312,984 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 12 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,312,984 Underlying: Common Stock · 1,312,984 shares Expires 2031-01-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4 · derivative.exercise_date: One-third of the option will vest on each of the three anniversaries after November 9, 2020. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 131,298 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 11 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 131,298 Underlying: Common Stock · 131,298 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 262,596 | Not disclosed Strike: $3.44 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 10 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 262,596 Underlying: Common Stock · 262,596 shares Expires 2026-09-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC |
Dougan Brady WDirector · 10% owner
|
GrantStock Options (right to buy) · Derivative | 157,558 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 9 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 157,558 Underlying: Common Stock · 157,558 shares Expires 2026-03-09 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.